Market Mastery

Are you a CEO building a high-stakes team for a novel therapeutic platform, pivotal clinical trial, or new R&D function? Don’t just observe, drive the process.

Explore how AI and digital tools are transforming regulatory affairs in the life sciences by automating documentation, enhancing predictive analytics, and streamlining compliance.

Here's a breakdown of the essential proficiencies that will help pharmacovigilance professionals thrive alongside AI.

In today’s high-stakes biotech environment, the timeline to IND (Investigational New Drug application) and first-in-human (FIH) studies is no longer just a benchmark of operational efficiency, it’s a critical determinant of funding, valuation, and survival.

One of the most notable trends of the past year has been the rise in startups opting to initiate early-phase clinical trials outside the United States, with countries like Australia and China emerging as favored destinations.

Amid rising geopolitical pressure and shifting trade policies, US-based CDMOs are booming—but talent shortages may hinder biotech's reshoring ambitions.

This article explores why 2025 will be a defining year for Regulatory Affairs in Biotech.

This article explores the top 5 challenges a CEO faces and how to overcome them.

This article explores the future of jobs in Biotech & Pharma under GOP leadership.

This article explores the pivotal role of clinical research in speeding up drug development, highlighting key lessons learned during the pandemic and the lasting changes to clinical trials.

In this article, we’ll delve into the evolving role of the biotech Chief Commercial Officer.

In this article, we’ll delve into why maintaining a high bar of quality for executive search in the life sciences is not just a best practice—it is a necessity.

In this article, we’ll delve into how interest rate cuts could provide a much-needed lifeline for emerging biotechs in 2025.

In this article, we’ll delve into why biotech and pharma firms should consider establishing PV capabilities earlier than conventionally practiced.

In this article, we’ll delve into why biotech and pharma firms should consider establishing PV capabilities earlier than conventionally practiced.